| Literature DB >> 29386141 |
Alessio Lorusso1, Soufien Sghaier2, Marco Di Domenico3, Mohamed Elias Barbria4, Guendalina Zaccaria3, Aida Megdich2, Ottavio Portanti3, Imed Ben Seliman5, Massimo Spedicato3, Federica Pizzurro3, Irene Carmine3, Liana Teodori3, Mejdi Mahjoub6, Iolanda Mangone3, Alessandra Leone3, Salah Hammami7, Maurilia Marcacci3, Giovanni Savini3.
Abstract
Bluetongue (BT), is one of the OIE-listed major diseases of ruminants. Following the official report of BT virus serotype 3 (BTV-3) in a sheep in Cap Bon (Tunisia), blood and serum samples of ruminants were collected from some areas of Tunisia to further investigate the presence of this virus in the country. A quantitative real time RT-PCR has been first developed for the detection and quantitation of BTV-3 RNA from field specimens. Out of 62 collected blood samples, 23 were shown to be positive for BTV-3 RNA. Isolation on cell cultures was also possible from six samples. Genome sequencing revealed the circulation of two unrelated western strains of BTV-3, one circulating in Cap Bon and neighboring areas, and the other circulating nearby the border with Libya. The presence of a putative novel BTV serotype (BTV-Y TUN2017) in sheep introduced from Libya to Tunisia, genomically related to the BTV strain contaminating a commercially-available sheep pox vaccine and to BTV-26, has been also demonstrated. This finding highlights the pressing need for a prompt production and release of a novel inactivated BTV-3 vaccine to be used in case of emergence or proactively in the areas of Southern Europe at major risk of BTV introduction. The assessment of a novel vaccine will certainly exalt the role and importance of surveillance activities and collaboration with Northern African countries.Entities:
Keywords: Bluetongue; Bluetongue serotype 3; Novel serotype; Surveillance; Tunisia
Mesh:
Substances:
Year: 2018 PMID: 29386141 DOI: 10.1016/j.meegid.2018.01.025
Source DB: PubMed Journal: Infect Genet Evol ISSN: 1567-1348 Impact factor: 3.342